Search and apply for every grant in existence.

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Focused Program Award – Rare Melanomas, supports a multidisciplinary research program of at least two, but not more than three, distinct but complementary research projects addressing an overarching question relevant to rare melanomas. Distinctive Features: · *Updated for FY26* Investigators must include at least one rare melanoma survivor or patient advocate as part of the project team who will provide advice and consultation throughout planning, implementation, and results dissemination to maximize research impact. · This is a partnering mechanism, requiring an Initiating Principal Investigator (PI) and at least one, but not more than two, Partnering PIs, see Figure 1. Each named PI is expected to be a Project Leader for one of the proposed research projects. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). · After submitting the required pre-application, investigators must receive an invitation to submit a full application. Only the Initiating PI will submit a pre-application. All PIs must submit full applications. The Partnering PI(s)’s application is an abbreviated package specific to their proposed research project. · Clinical trials are allowed. Funding Opportunity Number: HT942526MRPFPARM. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $5.6M total program funding.

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Team Science Award supports a broad range of hypothesis-driven, multidisciplinary studies that have a short-term goal of advancing the state of the science in melanoma research and/or patient care. Team science is a synergistic effort that harnesses techniques, approaches and perspectives from multiple disciplines and/or therapeutic areas to address complex, multi-dimensional problems that will impact patient outcomes. Distinctive Features: · This funding mechanism requires multiple Principal Investigators (PIs). At least two and up to three PIs should partner to jointly design and execute a single research project; multi-institutional partnerships are encouraged. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). · Consumer Collaboration Option: Investigators are encouraged, but not required, to form collaborative relationships with the melanoma consumer community to maximize the impact and translatability of the research for the benefit of the intended community(ies). · After submitting the required pre-application, investigators must receive an invitation to submit a full application. Only the Initiating PI will submit a pre-application. All PIs must submit full applications. The Partnering PI(s)’s application is an abbreviated package specific to their proposed research effort. Funding Opportunity Number: HT942526MRPTSA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $18.9M total program funding.

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO (PAR-23-286). Funding Opportunity Number: PAR-23-287. Assistance Listing: 93.398. Funding Instrument: G. Category: ED,HL.